← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
FitLife Brands delivered strong supplement growth and profit, but free cash flow lagged, inventory rose and a flagged screen tempers the otherwise attractive operating result.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 26.4%OK
- Profitability — Net income declined 29.6% to $6.326M from $8.984MWatch
- Cash flow — Free cash flow declined 22.9% to $7.397M from $9.6MWatch
- Margins — Operating margin contracted 800 bps to 12.35%Watch
- Accounting — Profitable growth with cash and inventory caveatsWatch
- Insiders — 3 purchases and 0 salesOK
Business
FitLife Brands markets nutritional supplements and wellness products through online channels, specialty retail and wholesale partners.
Where the revenue comes from
Fiscal 2025, as FITLIFE BRANDS, INC. reports it. History and quarterly detail are in the app.
- Legacy FitLife$62.0M
- Irwin$19.5M
Leadership changes
From FITLIFE BRANDS, INC.'s own filings, the day they're filed.
- Ryan Hansen · President · appointmenteff. 2026-05-18
- Shannon Pappas · member · appointmenteff. 2025-04-25
- Todd Ordal · departureeff. 2025-04-25
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- DEF 14A · Annual proxy (pay & governance)2026-06-26
- 8-K · Company announcement2026-05-22
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about FITLIFE BRANDS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.